Body composition // landing
Does Ipamorelin Cause Weight Gain? The Evidence
The animal weight-gain signal is real; the human body-composition data does not exist. Here is the distinction, cited.
The short version
Does ipamorelin cause weight gain? In animals, sometimes yes — and not in the way people expect. Two weeks of ipamorelin under the skin raised body weight by about 15% in mice and increased their fat pads and leptin (a fat-signaling hormone), and it did so even in mice that could not make growth hormone — meaning part of the weight effect bypasses growth hormone entirely [7]. Ipamorelin also acts on the ghrelin receptor, the body's hunger switch, which stimulates appetite [8]. So the honest answer for animals is that ipamorelin can add weight, partly as fat and partly through appetite. For humans there is no body-composition trial at all — the only human efficacy study was about bowel recovery after surgery, not weight [3]. Anything you read promising fat loss is extrapolation, not a measured ipamorelin result.
The animal weight-gain signal
The clearest weight result comes from a 2001 mouse study. Twice-daily subcutaneous ipamorelin for two weeks produced a roughly 15% body-weight increase in both growth-hormone-deficient (lit/lit) and growth-hormone-intact mice, with elevated fat-pad weights and serum leptin in both genotypes [7]. The fact that it happened in growth-hormone-deficient animals is the important part — it proves that some of ipamorelin's effect on adiposity and weight is growth-hormone-independent, operating directly through ghrelin-receptor signaling rather than through the growth-hormone pulse people focus on. A 2024 ferret study points the same direction from a different angle: intraperitoneal ipamorelin (1–3 mg/kg) inhibited chemotherapy-induced body-weight loss by about 24%, a weight-preserving (not weight-reducing) effect via a peripheral mechanism [5]. Both findings describe ipamorelin nudging the scale up or holding it up, not down.
Why the appetite mechanism matters
Ipamorelin is a ghrelin-receptor (GHS-R1a) agonist, and ghrelin is the body's hunger hormone. Acute central administration of ghrelin and growth-hormone secretagogues activates hypothalamic appetite centers and induces feeding in rats — the mechanistic basis for the orexigenic (appetite-raising) effect seen across this peptide class [8]. That is why weight gain is mechanistically plausible: more appetite, more intake, plus a direct adipogenic signal [7]. Ipamorelin's selectivity for growth hormone — its trademark feature of not raising cortisol or prolactin [1] — does not neutralize this appetite-and-fat side of the ghrelin mechanism. The two effects coexist.
The leaner-appearance reports, in context
If the animal data leans toward weight gain, why do some people report getting leaner? In research-use community accounts, a gradual shift toward a leaner appearance is occasionally reported, typically from about week five to week twelve of consistent use — described as subtle and slow (anecdotal, not clinical evidence). Two things to hold alongside that: first, these reports are uncontrolled and heavily confounded by the diet and training people run at the same time; second, the proposed mechanism is the growth-hormone pulse favoring lean tissue and lipolysis over time, which is plausible but unmeasured in any human body-composition trial. The bone-growth study is the cleanest lean-tissue signal — dose-dependent longitudinal growth in rats [4] — but it measured bone, not human fat. So "ipamorelin makes you lean" is a community impression, not an established outcome.
The honest bottom line on weight
The defensible summary: in animals, ipamorelin tends to add weight — partly fat, partly appetite-driven, partly growth-hormone-independent [7][8] — and can preserve weight against a catabolic insult [5]. In humans, there is no controlled body-composition data at all; the single human efficacy trial measured bowel recovery and missed its endpoint [3]. So the literature does not support ipamorelin as a fat-loss agent, and it provides a real mechanistic basis for the opposite in the short term. Reported leaner-body-composition outcomes exist but are anecdotal and confounded. For the full mechanism and the comparison with GHRH analogs, see the Ipamorelin research page.